351 related articles for article (PubMed ID: 25726054)
1. Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma.
Winner M; Goff SL; Chabot JA
Semin Oncol; 2015 Feb; 42(1):86-97. PubMed ID: 25726054
[TBL] [Abstract][Full Text] [Related]
2. A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer.
Goff SL; Chabot JA
Cancer J; 2012; 18(6):602-8. PubMed ID: 23187848
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
[TBL] [Abstract][Full Text] [Related]
4. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
5. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
[TBL] [Abstract][Full Text] [Related]
6. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
Kwon D; McFarland K; Velanovich V; Martin RC
Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
[TBL] [Abstract][Full Text] [Related]
7. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
[TBL] [Abstract][Full Text] [Related]
8. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer.
Kang CM; Hwang HK; Choi SH; Lee WJ
Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243
[TBL] [Abstract][Full Text] [Related]
9. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
[TBL] [Abstract][Full Text] [Related]
10. [Evolution in the therapeutic strategy of localized resectable pancreatic ductal adenocarcinoma].
Van Daele D; Puleo F; Dumont R; Polus M; Loly C; Martinive P; Meunier P; Collignon J; Hendlisz A; Maréchal R; Louis E; Van Laethem JL
Rev Med Suisse; 2015 Aug; 11(483):1543-8. PubMed ID: 26502580
[TBL] [Abstract][Full Text] [Related]
11. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
Loehrer AP; Ferrone CR
Dig Surg; 2016; 33(4):343-50. PubMed ID: 27216011
[TBL] [Abstract][Full Text] [Related]
13. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
[TBL] [Abstract][Full Text] [Related]
14. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.
Brown ZJ; Heh V; Labiner HE; Brock GN; Ejaz A; Dillhoff M; Tsung A; Pawlik TM; Cloyd JM
Br J Surg; 2022 Dec; 110(1):34-42. PubMed ID: 36346716
[TBL] [Abstract][Full Text] [Related]
15. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.
Álvarez R; Alés I; Díaz R; de Paredes BG; Hidalgo M
Clin Transl Oncol; 2017 Oct; 19(10):1193-1198. PubMed ID: 28612203
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research.
Cloyd JM; Tsung A; Hays J; Wills CE; Bridges JF
World J Gastroenterol; 2020 Jan; 26(4):375-382. PubMed ID: 32063686
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant therapy for localized pancreatic ductal adenocarcinoma.
Brown ZJ; Shannon AH; Cloyd JM
Minerva Surg; 2024 Jun; 79(3):315-325. PubMed ID: 38385797
[TBL] [Abstract][Full Text] [Related]
19. [CRITICAL VIEWPOINT ON THE CURRENT APPROACH OF LOCALIZED PANCREATIC DUCTAL ADENOCARCINOMA].
Van Daele D; Martinive P; Loly C; Polus M; Collignon J; Gast P; Louis E; Van Laethem JL
Rev Med Liege; 2015 Nov; 70(11):540-5. PubMed ID: 26738264
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma.
Tesfaye AA; Philip PA
Clin Adv Hematol Oncol; 2019 Jan; 17(1):54-63. PubMed ID: 30843899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
